Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

被引：6

作者：

Grant, H. ^{[1
]}

Jiang, X. ^{[2
,3
]}

Stebbing, J. ^{[4
]}

Foroni, L. ^{[5
]}

Craddock, C. ^{[6
]}

Griffiths, M. ^{[7
]}

Clark, R. E. ^{[8
]}

O'Brien, S. ^{[9
]}

Khorashad, J. S. ^{[5
]}

Gerrard, G. ^{[5
]}

Wang, L. ^{[8
]}

Irving, J. A. E. ^{[9
]}

Wang, M. ^{[10
]}

Karran, L. ^{[11
]}

Dyer, M. J. S. ^{[11
]}

Forrest, D. ^{[12
]}

Page, K. ^{[1
]}

Eaves, C. J. ^{[2
,3
]}

Woolfson, A. ^{[13
]}

机构：

[1] UCL, Dept Math, London, England

[2] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada

[3] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada

[4] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, Dept Med Oncol, London, England

[5] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, Dept Med, London, England

[6] Queen Elizabeth Hosp, Ctr Clin Haematol, Birmingham B15 2TH, W Midlands, England

[7] Birmingham Womens NHS Fdn Trust, W Midlands Reg Genet Lab, Birmingham, W Midlands, England

[8] Univ Liverpool, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England

[9] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[10] MRC, Mol Biol Lab, Div Prot & Nucle Acid Chem, Cambridge CB2 2QH, England

[11] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England

[12] British Columbia Canc Agcy, Div Hematol, Leukaemia BMT Program British Columbia, Vancouver, BC V5Z 4E6, Canada

[13] Bristol Myers Squibb Co, Discovery Med Oncol, Princeton, NJ USA

来源：

LEUKEMIA | 2010年 / 24卷 / 10期

基金：

英国医学研究理事会;

关键词：

RESISTANCE; MECHANISMS; INHIBITOR; IMATINIB;

D O I：

10.1038/leu.2010.179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1817 / 1821

页数：5

共 50 条

[21] The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
Clapper, Erin
Di Trapani, Giovanna
Tonissen, Kathryn F.
HEMATO, 2021, 2 (02): : 237 - 254
[22] Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
Polakova, Katerina Machova
Kulvait, Vojtech
Benesova, Adela
Linhartova, Jana
Klamova, Hana
Jaruskova, Monika
de Benedittis, Caterina
Haferlach, Torsten
Baccarani, Michele
Martinelli, Giovanni
Stopka, Tomas
Ernst, Thomas
Hochhaus, Andreas
Kohlmann, Alexander
Soverini, Simona
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) : 887 - 899
[23] Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
Tsubaki, Masanobu
Takeda, Tomoya
Matsuda, Takuya
Kimura, Akihiro
Tanaka, Remi
Nagayoshi, Sakiko
Hoshida, Tadafumi
Tanabe, Kazufumi
Nishida, Shozo
BMB REPORTS, 2023, 56 (02) : 78 - 83
[24] Comment on "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"
Kim, Sung-Hyun
Kim, Dong-Wook
HAEMATOLOGICA, 2015, 100 (03) : E120 - E121
[25] Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia
De, Surya K.
MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (03) : 424 - 433
[26] Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia
Martinez-Castillo, Macario
Gomez-Romero, Laura
Tovar, Hugo
Olarte-Carrillo, Irma
Garcia-Laguna, Anel
Barranco-Lampon, Gilberto
De la Cruz-Rosas, Adrian
Martinez-Tovar, Adolfo
Hernandez-Zavala, Araceli
Cordova, Emilio J.
LEUKEMIA RESEARCH, 2023, 131
[27] Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
Claudiani, Simone
Apperley, Jane F.
Khan, Afzal
Khorashad, Jamshid
Milojkovic, Dragana
HAEMATOLOGICA, 2020, 105 (05) : E225 - E227
[28] Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
Carter, Bing Z.
Mak, Po Yee
Mu, Hong
Wang, Xiangmeng
Tao, Wenjing
Mak, Duncan H.
Dettman, Elisha J.
Cardone, Michael
Zernovak, Oleg
Seki, Takahiko
Andreeff, Michael
HAEMATOLOGICA, 2020, 105 (05) : 1274 - 1284
[29] Distribution of BCR-ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia
Owojuyigbe, Temilola O.
Durosinmi, Muheez A.
Bolarinwa, Ramoni A. A.
Salawu, Lateef
Akinola, Norah O.
Ademosun, Abdulwaheed A.
Bosede, Oluwayomi T.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (04) : 646 - 651
[30] Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia
Gado, Sarah
Hassan, Mohammed Al-Kassim
Kisla, Mehmet Murat
Ates-Alagoz, Zeynep
MEDICINAL CHEMISTRY, 2024,

← 1 2 3 4 5 →